A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Trial Profile

A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Entinostat (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 To date 10 of planned 54 patients have been enrolled, according to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 25 Apr 2018 According to a Syndax Pharmaceuticals media release, results from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (2018).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top